Health and pharmacy retail chain Walgreens has pledged to contribute more than $25 million over the next five years to the Leukemia & Lymphoma Society and Susan G. Komen to fund research into metastatic breast and pediatric blood cancers as well as efforts to expand access to care, treatment, and support services.
To be raised through a combination of corporate donations and in-store fundraising, the funds will be split evenly between the two organizations, which are committed to supporting patient services and increasing access to screening and treatments locally and nationally. Susan G. Komen will use the funds to accelerate the pace of research discovery, particularly as it relates to understanding and combating breast cancer recurrence and metastasis; provide people living with breast cancer with reliable information; and help breast cancer patients overcome barriers to timely, high-quality care. LLS will use its share of the funds to accelerate the delivery of advances in cancer treatment to pediatric patients and help patients, caregivers, and survivors deal with the financial, emotional, and psychological impacts of cancer and its treatment.
"Our partnership with Walgreens is setting a new standard for what nonprofits and industry can do through collaboration to help more patients," said LLS president and CEO Louis DeGennaro. "Our investment of nearly $1.3 billion in cancer research is moving the needle, but new therapies can’t help patients who don’t have access to them. Through this partnership, we aim to reach more patients with critical support and services, in their communities."